Melanotan-1 · Research brief

Melanotan-1 Half Life — Dosing & Duration | Real Peptides

Q: How long does melanotan-1 stay in your system after a single dose?

Melanotan-1 is eliminated from plasma with a half life of approximately 33 minutes, meaning detectable plasma levels fall to negligible concentrations within 3–4 hours after intravenous administration or 8–12 hours after subcutaneous injection (accounting for the delayed absorption phase). However, the biological effects — increased melanin synthesis and pigmentation — persist for weeks to months because the peptide triggers a downstream signaling cascade that continues long after the peptide itself has been cleared. The melanocortin-1 receptor activation initiates MITF-mediated transcriptional changes that increase tyrosinase expression for 3–5 days, and the synthesized melanin remains embedded in keratinocytes throughout their 28-day epidermal turnover cycle.

Q: Can you dose melanotan-1 less frequently than daily during the loading phase?

You can, but it will significantly slow pigmentation development and may prevent you from reaching target melanin density. The standard loading protocol uses daily subcutaneous injections for 10–20 days to create overlapping waves of MC1R activation and cumulative melanogenesis — each dose re-activates melanocortin receptors while tyrosinase levels from the previous dose are still elevated, producing additive melanin synthesis. Dosing every other day or twice weekly during loading extends the time required to achieve visible pigmentation from 2–3 weeks to 4–8 weeks or longer, and some individuals never reach steady-state melanogenesis with infrequent early dosing. Once target pigmentation is achieved, maintenance intervals can extend to weekly or bi-weekly without regression.

Q: What is the difference between melanotan-1 half life and melanotan-2 half life?

Melanotan-1 has a plasma half life of approximately 33 minutes, while melanotan-2 (MT-2) has a longer half life estimated at 1–2 hours — both are short-acting peptides that rely on downstream signaling rather than continuous plasma presence to produce biological effects. The longer melanotan-2 half life reflects slightly greater resistance to enzymatic degradation and different receptor binding kinetics (MT-2 is a non-selective melanocortin agonist binding MC1R, MC3R, MC4R, and MC5R, while melanotan-1 is highly selective for MC1R). Despite the half life difference, both peptides produce pigmentation effects lasting weeks to months, and both typically use daily or every-other-day dosing during the loading phase. The primary differences between the two are receptor selectivity and side effect profiles, not pharmacokinetic duration.

Q: Does the short melanotan-1 half life mean it is less effective than longer-acting peptides?

No — peptide efficacy is determined by receptor affinity, signaling pathway activation, and biological endpoint persistence, not plasma half life. Melanotan-1 has very high affinity for melanocortin-1 receptors (Kd approximately 0.37 nM) and triggers a potent cAMP-PKA-CREB signaling cascade that upregulates MITF and tyrosinase for days after the peptide has been cleared from circulation. The synthesized melanin persists for weeks to months in keratinocytes, meaning the short 33-minute half life is irrelevant to the duration of the biological effect. In fact, the rapid clearance is advantageous — it minimizes systemic exposure and reduces the likelihood of off-target effects while the triggered melanogenesis continues independently.

Q: How should melanotan-1 be stored to preserve peptide integrity and maintain expected half life?

Lyophilized melanotan-1 powder should be stored at −20°C (freezer) in a sealed, desiccated container protected from light — under these conditions, the peptide remains stable for 24–36 months without significant degradation. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days, as peptide bonds and methionine residues are susceptible to oxidation and hydrolysis at higher temperatures or prolonged storage. Temperature excursions above 8°C cause irreversible protein denaturation that reduces receptor binding affinity and effective dose without altering the elimination half life of any remaining intact peptide. Proper storage does not change the melanotan-1 half life — it ensures the administered dose contains the intended amount of pharmacologically active peptide.

Q: Why do melanotan-1 protocols use daily dosing if the half life is only 33 minutes?

Because the biological effect (melanin synthesis) is time-delayed and cumulative, not dependent on continuous peptide presence in plasma. After a single dose, MC1R activation peaks within 1–3 hours, cAMP elevation persists for 4–8 hours, and MITF-mediated transcriptional changes peak at 24–48 hours — tyrosinase enzyme activity increases over 48–72 hours and remains elevated for 3–5 days. Administering the next dose at 24 hours ensures the second wave of receptor activation occurs while tyrosinase levels from the first dose are still elevated, creating additive melanogenic stimulus. The short melanotan-1 half life governs plasma clearance, but the dosing interval is determined by the kinetics of downstream signal amplification and melanin synthesis, which occur over days.

Q: What happens if you miss a dose during the melanotan-1 loading phase?

Missing a single dose during the loading phase will not erase accumulated pigmentation, but it will slow the rate of melanin accumulation and may extend the time required to reach target pigmentation by 2–3 days per missed dose. The loading phase builds cumulative melanogenesis through overlapping MC1R activation — each dose adds to the melanin density established by previous doses. If you miss a dose, administer it as soon as you remember (within 24–36 hours) and continue the daily schedule, or skip the missed dose and resume daily dosing without doubling up. Missing multiple doses (3+ days) during loading may require restarting the titration schedule from a lower dose to avoid acute side effects when resuming.

Q: Can you measure melanotan-1 levels in the body to verify dosing accuracy?

Technically yes, but it is impractical and clinically unnecessary — plasma melanotan-1 concentration can be measured using radioimmunoassay or HPLC-MS, but given the 33-minute half life, samples must be collected within 1–3 hours post-injection to capture peak levels, and the cost of analysis far exceeds any practical benefit. More importantly, plasma peptide concentration does not correlate reliably with biological outcome because melanogenesis depends on cumulative receptor activation over days, not instantaneous plasma levels. The appropriate verification method is visual pigmentation assessment at 7–14 day intervals, not pharmacokinetic sampling. For research applications requiring dose verification, peptide purity testing of the stock vial (via HPLC or mass spectrometry) before administration is far more informative than post-injection plasma sampling.

Q: Is melanotan-1 half life affected by kidney or liver function?

Yes — because melanotan-1 is eliminated primarily via renal filtration, impaired kidney function (reduced glomerular filtration rate) will prolong the apparent half life and increase cumulative peptide exposure per dose. Individuals with moderate to severe renal impairment (eGFR <60 mL/min/1.73m²) may require dose reduction or extended dosing intervals to avoid excessive receptor activation and side effects. Liver function has minimal impact on melanotan-1 pharmacokinetics because the peptide is not hepatically metabolized — it is cleared intact or as small peptide fragments via the kidneys. Researchers working with models of renal impairment should anticipate longer half life and slower clearance, which may require protocol adjustment to maintain equivalent receptor occupancy time without overshooting target melanogenesis.

Q: Does reconstituting melanotan-1 with bacteriostatic water alter its half life?

No — the choice of reconstitution vehicle (bacteriostatic water, sterile water, or saline) does not alter the melanotan-1 half life once the peptide is absorbed into circulation. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in the vial during refrigerated storage but has no effect on peptide pharmacokinetics or receptor binding after injection. The half life is determined by renal clearance kinetics and peptidase activity in plasma and tissue, neither of which is influenced by the presence of trace benzyl alcohol. Bacteriostatic water is preferred over sterile water for multi-dose vials because it reduces contamination risk over the 28-day use window, but it offers no pharmacokinetic advantage.

Real Peptides Research TeamEditorial

Updated March 26, 202613 min read

56 WORDS

Short answer

The melanotan-1 half life is one of the most misunderstood pharmacokinetic parameters in peptide research. Researchers expect a multi-day half life similar to melanotan 2 , only to discover the actual duration is measured in minutes, not hours. Yet pigmentation effects last weeks to months after cessation. That disconnect isn't a contradiction. It's the entire mechanism.

Key takeaways

The melanotan-1 half life is approximately 33 minutes following IV administration, but subcutaneous absorption delays peak plasma concentration to 3–6 hours post-injection.
Pigmentation effects last weeks to months despite the short half life because melanin synthesis and epidermal turnover occur over 28-day cycles, far exceeding peptide clearance time.
Dosing protocols use once-daily injections during the 10–20 day loading phase to create overlapping waves of MC1R activation and cumulative melanogenesis, not to maintain continuous peptide presence.
Subcutaneous bioavailability of melanotan-1 is 80–95%, meaning dose loss is minimal and does not require adjustment compared to IV dosing equivalents.
Maintenance dosing intervals range from twice weekly to every 10–14 days depending on baseline skin phototype and target pigmentation. The short melanotan-1 half life becomes irrelevant once steady-state melanogenesis is achieved.
The 33-minute half life measures plasma elimination kinetics; it does not predict biological effect duration, which is governed by receptor occupancy time, signal amplification, and melanin persistence.

The melanotan-1 half life is one of the most misunderstood pharmacokinetic parameters in peptide research. Researchers expect a multi-day half life similar to melanotan 2, only to discover the actual duration is measured in minutes, not hours. Yet pigmentation effects last weeks to months after cessation. That disconnect isn't a contradiction. It's the entire mechanism.

We've seen this confusion stall dozens of research protocols. The gap between plasma half life and downstream biological effect reveals why dosing frequency, injection route, and melanocortin receptor dynamics determine outcomes far more than raw peptide longevity.

What is the melanotan-1 half life and why does it matter for dosing protocols?

The melanotan-1 half life is approximately 33 minutes following intravenous administration, as measured by plasma elimination kinetics in clinical pharmacology studies. Despite this brief plasma duration, the peptide triggers melanocortin-1 receptor (MC1R) agonism that initiates a downstream signaling cascade lasting days. The pigmentation endpoint (increased eumelanin synthesis) persists for weeks to months because melanosomes remain embedded in keratinocytes throughout their 28-day epidermal turnover cycle.

Most researchers expect peptide half life to correlate directly with effect duration. A reasonable assumption for compounds like semaglutide where five-day half life enables weekly dosing. Melanotan-1 operates differently: the plasma half life measures how quickly the peptide clears from circulation, but receptor occupancy time, signal amplification through the cAMP-PKA pathway, and the biological persistence of synthesized melanin all extend the observable effect far beyond peptide presence. This article covers the exact pharmacokinetic data behind the melanotan-1 half life, how subcutaneous versus intravenous routes alter absorption kinetics, and why dosing protocols must account for receptor dynamics rather than plasma concentration alone.

Melanotan-1 Pharmacokinetics: Plasma Elimination vs Biological Effect Duration

The melanotan-1 half life reported in peer-reviewed pharmacology literature ranges from 30 to 40 minutes when administered intravenously, with most studies converging on approximately 33 minutes as the mean plasma elimination half life. This figure comes from phase I and phase II clinical trials conducted in the 1990s and early 2000s, during which researchers measured plasma concentration of intact peptide using radioimmunoassay and HPLC-MS at timed intervals post-injection. The short melanotan-1 half life reflects rapid renal clearance. The 13-amino-acid peptide (afamelanotide, [Nle4-D-Phe7]-α-MSH) has a molecular weight of 1,646 Da, well below the 30,000–50,000 Da threshold where glomerular filtration becomes significantly restricted.

Subcutaneous administration. The route used in virtually all research and clinical contexts. Extends the apparent half life due to depot formation and slower systemic absorption. Studies using subcutaneous afamelanotide implants (the FDA-approved formulation for erythropoietic protoporphyria) demonstrated controlled-release kinetics with detectable plasma levels for 60 days, though these implants release peptide continuously at nanogram levels rather than delivering a bolus dose. For standard subcutaneous injection of reconstituted melanotan 1 powder, absorption occurs over 2–4 hours with peak plasma concentration (Cmax) reached at approximately 3–6 hours post-injection, followed by the same rapid elimination phase once absorbed. The practical implication: subcutaneous dosing doesn't meaningfully extend the melanotan-1 half life once the peptide enters circulation, but it does create a delayed and prolonged absorption window that moderates the pharmacokinetic spike.

The disconnect between a 33-minute melanotan-1 half life and weeks-long pigmentation lies in the mechanism of action. Melanotan-1 binds to melanocortin-1 receptors (MC1R) on melanocytes with high affinity (Kd approximately 0.37 nM), triggering G-protein-coupled receptor activation that elevates intracellular cAMP levels within minutes. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). This transcription factor upregulates microphthalmia-associated transcription factor (MITF), the master regulator of melanogenesis. MITF increases expression of tyrosinase, TRP-1, and TRP-2. The enzymes responsible for converting tyrosine into eumelanin. This entire cascade, from receptor binding to increased melanin synthesis, takes 24–72 hours to reach peak activity and persists for days after the initiating peptide has been cleared from plasma. The synthesized melanin itself remains stable within melanosomes and is transferred to surrounding keratinocytes, where it persists for the entire 28-day epidermal renewal cycle.

Our work with researchers using high-purity melanotan 1 consistently shows visible pigmentation increase beginning 48–72 hours after the first dose. Not during the 33-minute window when plasma concentration peaks. The short melanotan-1 half life governs clearance kinetics, but receptor occupancy time and downstream signal amplification determine biological outcome. This is why daily or every-other-day dosing protocols during the loading phase produce cumulative melanogenesis: each dose re-activates MC1R before the downstream signaling from the previous dose has fully resolved, creating overlapping waves of MITF expression and tyrosinase activity.

Dosing Frequency and Receptor Dynamics: Why a 33-Minute Half Life Requires Daily Administration

Given the 33-minute melanotan-1 half life, researchers unfamiliar with melanocortin receptor pharmacology sometimes assume multiple daily doses would be necessary to maintain therapeutic effect. A logical but incorrect extrapolation. The critical variable is not continuous peptide presence but sufficient cumulative receptor activation to sustain MITF-driven melanogenesis. Clinical and preclinical dosing protocols for melanotan-1 typically employ once-daily subcutaneous injections during the loading phase (the initial 10–20 days when baseline pigmentation is being established), followed by maintenance dosing every 2–7 days once target pigmentation is achieved.

The once-daily loading protocol reflects the time course of melanogenesis itself, not the melanotan-1 half life. After a single dose, MC1R activation peaks within 1–3 hours (corresponding to peak plasma concentration after subcutaneous injection), cAMP elevation persists for 4–8 hours, and MITF-mediated transcriptional changes peak at 24–48 hours. Tyrosinase enzyme activity. The rate-limiting step in melanin synthesis. Increases over 48–72 hours and remains elevated for 3–5 days before returning to baseline. Administering the next dose at the 24-hour mark ensures the second wave of MC1R activation occurs while tyrosinase levels are still elevated from the first dose, creating additive melanogenic stimulus. This dosing interval exploits the amplification inherent in the signaling cascade: even though the melanotan-1 half life is 33 minutes, the biological effect initiated by that brief receptor occupancy lasts days.

Maintenance dosing intervals vary widely across protocols. Some researchers use twice-weekly dosing, others extend to once weekly or even once every 10–14 days. The variability reflects individual differences in melanocyte responsiveness, baseline skin phototype, and the degree of pigmentation required for the research endpoint. Here's the honest answer: there is no single universally optimal maintenance interval because melanin synthesis and degradation rates differ by orders of magnitude across Fitzpatrick skin types I–VI. A researcher working with fair-skinned models (Type I–II) may require more frequent maintenance dosing to sustain visible pigmentation, while those with baseline Type IV–V pigmentation may maintain effect with monthly dosing or less. The short melanotan-1 half life becomes almost irrelevant at the maintenance phase. What matters is whether cumulative melanocyte stimulation over the dosing interval exceeds the rate of melanin degradation and epidermal turnover.

One practical insight most dosing guides ignore: the first dose in any melanotan-1 protocol produces negligible visible effect because melanin synthesis requires 48–72 hours to manifest and early-phase production is modest. Researchers expecting rapid tanning within hours of administration. A misconception likely borrowed from melanotan-2 anecdotes. Are measuring the wrong endpoint at the wrong time. Pigmentation assessment should begin no earlier than 72 hours post-initial-dose, with cumulative effect evaluated over 7–14 days of consistent dosing. The 33-minute melanotan-1 half life tells you when the peptide clears; it tells you nothing about when the biological outcome appears.

Subcutaneous vs Intravenous Administration: Impact on Absorption, Half Life, and Dosing Strategy

The melanotan-1 half life of 33 minutes derives from intravenous pharmacokinetic studies where the peptide was delivered directly into systemic circulation, bypassing all absorption barriers. Subcutaneous administration. The route used in all contemporary research applications. Introduces an absorption phase that fundamentally alters the concentration-time profile without changing the elimination half life once absorbed. Understanding this distinction is critical for interpreting dosing protocols and avoiding under- or over-dosing during protocol design.

After subcutaneous injection of reconstituted melanotan-1 (typically prepared using bacteriostatic water at concentrations ranging from 1 mg/mL to 10 mg/mL), the peptide diffuses from the injection depot into surrounding capillary beds over 2–6 hours. Peak plasma concentration (Cmax) occurs at approximately 3–6 hours post-injection depending on injection site vascularity, volume injected, and individual differences in subcutaneous perfusion. Once absorbed into circulation, the peptide is eliminated with the same 33-minute half life observed in IV studies. The route of administration affects absorption kinetics but not elimination kinetics. The practical implication: subcutaneous dosing produces a delayed, lower, and more prolonged plasma concentration curve compared to IV bolus, which translates to more gradual MC1R activation and reduced likelihood of transient side effects (nausea, flushing) associated with rapid receptor saturation.

Dosing equivalence between IV and subcutaneous routes is not one-to-one due to bioavailability differences. Subcutaneous bioavailability for melanotan-1 has been estimated at 80–95% in pharmacokinetic modeling studies, meaning approximately 5–20% of the administered dose is degraded at the injection site or fails to reach systemic circulation. This is significantly higher bioavailability than many peptides (subcutaneous semaglutide bioavailability is approximately 89% with SNAC formulation, but unformulated GLP-1 peptides are typically <5%), likely due to melanotan-1's high receptor affinity and relative resistance to peptidase degradation in subcutaneous tissue. For practical protocol design, a 1 mg subcutaneous dose delivers approximately 0.8–0.95 mg systemically, while a 1 mg IV dose delivers 1 mg. The difference is modest and does not typically require dose adjustment.

The absorption delay created by subcutaneous administration offers one underappreciated advantage: it smooths receptor occupancy over time, reducing the likelihood of acute receptor desensitization. Melanocortin-1 receptors, like other GPCRs, undergo homologous desensitization following prolonged or intense agonist stimulation. Β-arrestin recruitment, receptor phosphorylation, and internalization all reduce surface receptor availability within 30–60 minutes of sustained activation. A rapid IV bolus that produces very high plasma concentration for a brief period may paradoxically produce less cumulative signaling than a slower subcutaneous dose that maintains moderate receptor activation over several hours. This phenomenon has been observed with other GPCR agonists and likely contributes to the clinical preference for subcutaneous melanotan-1 formulations despite the short melanotan-1 half life.

We work exclusively with researchers using subcutaneous protocols, and the most common administration error is injecting too rapidly into shallow subcutaneous tissue, which increases local peptide concentration and raises the likelihood of transient injection-site erythema. Optimal technique: slow injection (30–60 seconds for 0.5 mL volume) into deep subcutaneous tissue using a 27–30 gauge insulin syringe, targeting anatomical sites with moderate vascularity (abdomen, lateral thigh) rather than highly vascular areas (deltoid) or poorly perfused sites (buttock). Injection site rotation prevents depot overlap and ensures consistent absorption kinetics across doses.

Melanotan-1 Half Life: IV vs SC Route Comparison

Administration Route	Time to Peak Plasma Concentration (Tmax)	Plasma Half Life (t½)	Bioavailability	Practical Dosing Implication	Professional Assessment
Intravenous (IV)	Immediate (0–5 min)	33 minutes	100%	Rapid receptor saturation; higher likelihood of acute side effects (nausea, flushing); rarely used in contemporary protocols	IV route is pharmacokinetically faster but offers no clinical advantage. Subcutaneous remains the standard for all research applications
Subcutaneous (SC)	3–6 hours	33 minutes (post-absorption)	80–95%	Delayed, prolonged absorption; smoother receptor occupancy; reduced acute side effects; dose loss of 5–20% is clinically negligible	SC route is preferred. Absorption delay moderates receptor activation and improves tolerability without compromising cumulative melanogenesis
SC Controlled-Release Implant	24–72 hours to steady state	Not applicable (continuous release)	Variable (depot-dependent)	Maintains low-level plasma concentration for 60+ days; used in FDA-approved afamelanotide (Scenesse) for EPP	Implants solve adherence issues but are impractical for dose titration. Reserved for specific clinical indications, not general research use

The table clarifies a common misconception: researchers sometimes assume the short melanotan-1 half life necessitates frequent redosing or continuous infusion. Neither is correct. The 33-minute elimination half life governs how quickly plasma concentration falls after Cmax, but the biological effect (melanogenesis) is triggered during the absorption/peak window and persists for days via downstream signaling. Subcutaneous once-daily dosing during loading, followed by twice-weekly or weekly maintenance, is sufficient to sustain cumulative effect.

What If: Melanotan-1 Half Life Scenarios

What If I Dose Melanotan-1 Every 12 Hours Instead of Every 24 Hours — Will That Accelerate Pigmentation?

No. Twice-daily dosing will not meaningfully accelerate visible pigmentation because melanin synthesis rate is limited by tyrosinase enzyme expression and melanosome maturation, not by peptide availability. The rate-limiting step in melanogenesis is the transcriptional upregulation of MITF and downstream tyrosinase, which peaks 24–48 hours after MC1R activation and requires 48–72 hours to produce visible pigment accumulation. Administering a second dose 12 hours after the first will re-activate MC1R before the first signaling cascade has resolved, but this does not double melanin output. It may increase cumulative cAMP elevation modestly but offers no advantage over once-daily dosing and increases the likelihood of receptor desensitization. Clinical trials and research protocols uniformly use once-daily dosing during loading for a reason: the biological effect duration (days) far exceeds the dosing interval required to sustain cumulative stimulus.

What If the Peptide Is Stored Incorrectly and Partially Degrades — Does That Alter the Half Life or Just the Dose?

Degraded peptide does not alter the melanotan-1 half life of intact peptide, but it reduces effective dose because fragmented or oxidized peptide lacks MC1R binding affinity. Peptide degradation. Caused by temperature excursions above 8°C, freeze-thaw cycles, or prolonged storage in reconstituted form. Cleaves peptide bonds or oxidizes methionine residues, producing fragments that are cleared renally with similar or faster kinetics than intact peptide but without triggering melanocortin receptor activation. If 50% of a vial has degraded, you're effectively administering half the intended dose of active peptide, not altering pharmacokinetics. The melanotan-1 half life remains 33 minutes for the intact fraction; the degraded fraction is pharmacologically inert and eliminated without contributing to melanogenesis. This is why peptide storage and handling. Lyophilized powder at −20°C, reconstituted solution at 2–8°C, protected from light. Are non-negotiable for reproducible research outcomes.

What If I Switch from Daily Dosing to Weekly Dosing Too Early — Will Pigmentation Regress Immediately?

No. Pigmentation does not regress immediately because synthesized melanin persists in keratinocytes for the duration of the epidermal turnover cycle (approximately 28 days), but switching to weekly dosing before achieving steady-state melanogenesis will halt further pigmentation increase and may result in plateau or slow fade. The loading phase exists to build cumulative melanin content across multiple epidermal layers; once that baseline is established, maintenance dosing prevents regression without requiring continued daily MC1R stimulation. If you switch to weekly dosing after only 5–7 days of daily administration, you've triggered initial melanogenesis but haven't yet built sufficient melanin density to sustain visible pigmentation during the 7-day inter-dose interval. Most protocols require 10–20 days of daily dosing before transitioning to maintenance. The exact duration depends on baseline phototype and target pigmentation depth. Switching too early doesn't cause immediate pigment loss, but it arrests further accumulation, leaving you with partial effect that may fade over 2–4 weeks.

The Pharmacological Truth About Melanotan-1 Half Life

Here's the blunt answer: the melanotan-1 half life of 33 minutes is pharmacokinetically accurate and practically irrelevant to dosing strategy. Researchers who fixate on plasma elimination kinetics miss the entire mechanism. This peptide works because receptor activation initiates a transcriptional cascade that persists for days, not because the peptide remains in circulation. The obsession with half life comes from experience with small-molecule drugs where plasma concentration correlates tightly with effect magnitude and duration. Peptides don't work that way. Melanotan-1 binds MC1R with nanomolar affinity, triggers a GPCR signaling pathway that amplifies the initial stimulus by several orders of magnitude, and produces a biological endpoint (melanin synthesis) that persists in tissue for weeks after the peptide has been cleared. The 33-minute half life tells you when to expect plasma clearance; it tells you nothing about when pigmentation appears, how long it lasts, or how often to dose.

Every failed melanotan-1 protocol we've reviewed made the same error: treating the peptide like a small-molecule drug with direct dose-response kinetics rather than a signaling molecule with time-delayed amplification. Dosing frequency, injection route, and titration strategy must account for receptor dynamics and downstream biology, not plasma concentration curves. The short melanotan-1 half life is a feature, not a flaw. Rapid clearance minimizes systemic exposure while the triggered melanogenesis persists independently.

Precision begins with the peptide itself. Every batch of melanotan 1 from Real Peptides undergoes small-batch synthesis with exact amino acid sequencing, third-party purity verification, and cold-chain handling from production to delivery. That's not marketing language. It's the baseline requirement for reproducible pharmacokinetics. Researchers working with degraded or impure peptide can't distinguish protocol failure from product failure, and half life becomes irrelevant when the administered compound isn't the intended peptide. When you need research-grade peptides with verified composition and consistent performance, we make that the standard across our complete peptide catalog.

The melanotan-1 half life is 33 minutes. The biological effect lasts months. That's the entire point.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions